Details:

Alternative Title:
Clin Infect Dis
Personal Author:
Bard, Jennifer Dien ; Hindler, Janet A. ; Gold, Howard S. ; Limbago, Brandi
Bard, Jennifer Dien ; Hindler, Janet A. ; Gold, Howard S. ; Limbago, Brandi Less -
Description:
Due to the ongoing concern about the reliability of Staphylococcus breakpoints (interpretive criteria) for other β-lactam agents, the Clinical and Laboratory Standards Institute recently approved the elimination of all breakpoints for antistaphylococcal β-lactams except for penicillin, oxacillin or cefoxitin, and ceftaroline. Routine testing of penicillin and oxacillin or cefoxitin should be used to infer susceptibility for all β-lactams with approved clinical indications for staphylococcal infections. It is critical for laboratories to reject requests for susceptibility testing of other β-lactams against staphylococci and to indicate that susceptibility to these agents can be predicted from the penicillin and oxacillin or cefoxitin results. This article reviews β-lactam resistance mechanisms in staphylococci, current antimicrobial susceptibility testing and reporting recommendations for β-lactams and staphylococci, and microbiologic data and clinical data supporting the elimination of staphylococcal breakpoints for other β-lactam agents.
Subject:
[+]
Anti-Bacterial Agents
Beta-Lactam Resistance
Beta-Lactams
Cefoxitin
Cephalosporins
Humans
Microbial Sensitivity Tests
Oxacillin
Penicillins
Staphylococcal Infections
Staphylococcus

Source:
Clin Infect Dis. 58(9):1287-1296.
Pubmed ID:
24457339
Pubmed Central ID:
PMC5734619
Document Type:
Journal Article
Funding:
CC999999/Intramural CDC HHS/United States
Name as Subject:
United States. Food and Drug Administration.
Place as Subject:
United States
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:532ba40db810c020370a1e29edefbe7862cedad355fd9b79241d140409fa8700
File Type:

Supporting Files

• nihms732272.nxml

  xml

More +